GB-0895
Severe Asthma
Key Facts
About Generate Biomedicines
Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.
View full company profileAbout Generate Biomedicines
Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.
View full company profileTherapeutic Areas
Other Severe Asthma Drugs
| Drug | Company | Phase |
|---|---|---|
| Nucala (mepolizumab) | GSK plc | Approved |
| Verekitug | Upstream Bio | Phase 2 |